The Gm & Cheshire Life Sciences Fund L.P investment portfolio

Bitrobius Genetics develops the Gentrafix™ platform, a plasmid‑based technology that delivers therapeutic DNA to every affected cell through intercellular transmission, aiming to treat genetic diseases, including those caused by mitochondrial gene mutations. The company targets the gene‑therapy market for diseases that currently have no effective treatments.

CanCertain Ltd operates a laboratory that uses advanced 3D cell‑culture technology to provide personalised cancer‑treatment tests, identifying the most effective therapy for a patient’s tumour within about eight working days. Its services are directed at patients and their families, as well as oncologists, hospitals and insurers seeking rapid, tailored treatment recommendations.